ANTIMONY CATION (5+)

Summary

Antimony Cation (5+) (CHEMBL4297415) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including mucocutaneous leishmaniasis and cutaneous leishmaniasis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297415
Name	ANTIMONY CATION (5+)
Type	Small molecule
Max phase	3

Also known as: Antimony cation (5+), Pentavalent antimony, ANTIMONY CATION (5+)

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
mucocutaneous leishmaniasis	3	MONDO:0005859	EFO:0007379
cutaneous leishmaniasis	2	MONDO:0005446	EFO:0005046

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01300975	PHASE2	COMPLETED	Intralesional Antimony for Bolivian Cutaneous Leishmaniasis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).